Skip to main
BIOR
BIOR logo

BIOR Stock Forecast & Price Target

BIOR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biora Therapeutics Inc is positioned for growth due to anticipated increases in business development and collaboration activities, which could bolster its program advancements. The introduction of the smaller BioJet device enhances usability, potentially leading to greater market penetration and a wider range of suitable therapeutic molecules. Furthermore, positive results from the BT-600 Phase 1 trial and ongoing progress with the NaviCap device support a favorable outlook regarding clinical success and potential expansion of Biora's asset portfolio.

Bears say

Biora Therapeutics Inc. faces substantial risks that negatively impact its financial outlook, primarily due to potential failures or inconclusive results from its clinical trials, particularly concerning its BT-600 program and the NaviCap platform. Additionally, the company struggles with securing sufficient funding to advance its product development, which could lead to further dilutive capital raises. Compounding these issues is the significant amount of convertible debt on Biora's balance sheet, posing considerable dilutive risk over the next several years.

BIOR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biora Therapeutics Inc (BIOR) Forecast

Analysts have given BIOR a Strong Buy based on their latest research and market trends.

According to 1 analysts, BIOR has a Strong Buy consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biora Therapeutics Inc (BIOR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.